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Autologous skeletal muscle derived 
cells expressing a novel functional 
dystrophin provide a potential 
therapy for Duchenne Muscular 
Dystrophy
Jinhong Meng1, John R. Counsell1,2,4, Mojgan Reza3, Steven H. Laval3, Olivier Danos2,†, 
Adrian Thrasher4, Hanns Lochmüller3, Francesco Muntoni1 & Jennifer E. Morgan1
Autologous stem cells that have been genetically modified to express dystrophin are a possible means 
of treating Duchenne Muscular Dystrophy (DMD). To maximize the therapeutic effect, dystrophin 
construct needs to contain as many functional motifs as possible, within the packaging capacity of the 
viral vector. Existing dystrophin constructs used for transduction of muscle stem cells do not contain the 
nNOS binding site, an important functional motif within the dystrophin gene. In this proof-of-concept 
study, using stem cells derived from skeletal muscle of a DMD patient (mdcs) transplanted into an 
immunodeficient mouse model of DMD, we report that two novel dystrophin constructs, C1 (ΔR3-R13) 
and C2 (ΔH2-R23), can be lentivirally transduced into mdcs and produce dystrophin. These dystrophin 
proteins were functional in vivo, as members of the dystrophin glycoprotein complex were restored in 
muscle fibres containing donor-derived dystrophin. In muscle fibres derived from cells that had been 
transduced with construct C1, the largest dystrophin construct packaged into a lentiviral system, nNOS 
was restored. The combination of autologous stem cells and a lentivirus expressing a novel dystrophin 
construct which optimally restores proteins of the dystrophin glycoprotein complex may have 
therapeutic application for all DMD patients, regardless of their dystrophin mutation.
Duchenne Muscular Dystrophy (DMD) is a severe inherited muscle disease that affects 1 in 5,000 newborn boys1. 
The lack of dystrophin2,3 leads to continuous cycles of degeneration and regeneration of muscle fibres and at the 
later stages of the disease, replacement of muscle by fat or fibrotic tissue, which greatly compromises muscle 
function.
Stem cell therapy is a promising strategy for the treatment of DMD, as transplanted stem cells fuse with exist-
ing muscle fibres and restore functional dystrophin expression at the sarcolemma, to prevent further progres-
sion of the disease. Stem cells isolated from human skeletal muscle4–7 have been shown to contribute to muscle 
regeneration after transplantation into animal models. Among these, human skeletal muscle derived pericytes5, 
or similar muscle derived cells (mdcs)6 and CD133+ cells4,7,8 are particularly effective. Transplantation of muscle 
stem cells isolated from a normal donor into patient muscle (allograft) will restore full length, functional dystro-
phin protein in regenerated muscle fibres, but this would elicit immune rejection. To avoid this, an ex vivo strategy 
can be implemented, involving autologous transplantation of the patient’s stem cells following genetic correction 
in vitro.
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Lentiviruses are able to transduce non-dividing and dividing cells, leading to stable and long-term gene 
expression9, but they only have a small cloning capacity10 and therefore cannot accommodate the cDNA of full 
length dystrophin (>11 Kb). To circumvent this limitation, truncated forms of dystrophin have been developed, 
retaining dystrophin domains thought to serve essential functions11,12. However, not all of these truncated dys-
trophins are fully functional. Most dystrophin constructs that have been used in combination with experimental 
cell transplantation strategies lack the spectrin repeats 16 and 17 (R16–17), which is a well-recognized nNOS 
binding site13,14, thus would not exert the signaling function via the nNOS pathway. We therefore developed 
2 novel mini-dystrophin constructs, a 4.2 Kb Δ H2–R23 (C2) construct which contained only the critical func-
tional motifs of the dystrophin and Δ R3–R13 (C1), a large dystrophin construct near the size limit of the packag-
ing capacity of the lentivirus. Importantly, C1 contains the nNOS binding site-spectrin repeats 16 and 17. These 
constructs were lentivirally-transduced into human muscle stem cells and their efficacy compared.
For clinical application, it is desirable that dystrophin expression occurs only in cells of the muscle lineage, so 
the use of viral promoters, such as cytomegalovirus (CMV) or spleen focus-forming virus (SFFV), that would drive 
gene expression in all cell types, would not be ideal. One muscle specific promoter, the human desmin (hDesmin) 
promoter offers a comparable level of transgene expression to CMV15 and SFFV promoters16. In light of this, we 
employed the hDesmin promoter in our investigations, with the additional advantage of restricting transgene 
expression to myogenic cells. However, the large size of the hDesmin promoter (1.8 Kb) presented a technical 
drawback. To circumvent this limitation and enable efficient packaging of larger dystrophin constructs, we also 
produced lentiviral vectors expressing dystrophin under the control of the much smaller SFFV promoter (412 bp).
We show that cells derived from skeletal muscle of a DMD patient6 can be transduced with lentiviruses 
expressing dystrophin constructs. Dystrophin protein was produced by these cells in vitro and in regenerated 
muscle fibres of donor origin within host mdx nude mouse muscles that had been grafted with donor cells. In 
the regenerated muscle fibres that expressed dystrophin, components of the dystrophin-associated glycoprotein 
complex (DGC) were restored in a dose-dependent manner. In fibres expressing dystrophin C1, nNOS was also 
present at the sarcolemma, suggesting that the C1 dystrophin construct is superior to C2 in that it can also restore 
the nNOS signaling pathway in vivo.
Results
Generation of dystrophin lentivirus and titration. The structure of the dystrophin constructs exam-
ined in our study is shown in Fig. 1A. The sizes (from 5′ -3′ UTR) of construct C1 and C2 are 7.4 Kb and 4.2 Kb 
respectively. After being cloned into the lentiviral vector, under different promoters, some of the lentiviral con-
structs constituted more than 10 Kb between the flanking LTRs (Fig. 1B), which is beyond the optimal range of 
lentivirus packaging capacity10,17. In order to assess the efficiency of viral delivery of large constructs, lentivi-
ruses containing SFFV-C1-GFP, SFFV-C2-GFP, hDesmin-C1-GFP or hDesmin-C2-GFP were produced using 
a third-generation lentiviral packaging system18 and titred by a range of methods (Fig. 1B) and compared to 
a smaller pRRL.SFFV.neo-IRES-GFP-WPRE construct (NIGW, 5310 bp). Titration of the total viral RNA copy 
number and the transduced proviral copy number showed a trend towards reduced vector titre as the length 
of packaged sequence increased. However, Alu-PCR titration highlighted that lentiviral integration efficiency 
reduced at a greater rate as the length of packaged sequence exceeded 11.5 kb. This profile was confirmed by FACS 
titration, which highlighted a sharp drop in functional titre above the 11.5 kb level. Given that non-integrating 
vectors are reported to express with a lower intensity than integrated proviruses19, this reduced rate of integration 
may partly explain the rapid drop-off in FACS titre experienced with larger vectors.
Dystrophins C1 and C2 were successfully transduced into DMD pericytes. Cells derived from 
the skeletal muscle of a DMD patient6 were transduced with lentivirus coding for mini-dystrophin constructs 
SFFV-C1-GFP, hDesmin-C1-GFP, SFFV-C2-GFP, and hDesmin-C2-GFP using an MOI of 10 (according to the pro-
viral copy number). Lentiviruses coding for hDesmin-GFP or SFFV-GFP were used as controls. The transduction 
efficiency was examined by FACS, 7 days after transduction (Figure S1). There were 59.3%, 6.53%, 71.3% and 50.2% 
GFP+ cells within SFFV-C1-GFP, hDesmin-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP transduced cells, 
respectively, and 92.6% and 87.9% GFP+ cells within SFFV-GFP and hDesmin-GFP lentivirus-transduced cells.
Dystrophin protein is produced in transduced non-differentiated cells. GFP+ cells were purified 
by FACS and expanded in vitro for analysis. Double staining with GFP and dystrophin antibodies confirmed that 
they were, as expected, co-localized in cells transduced with SFFV-C1-GFP, hDesmin-C1-GFP, SFFV-C2-GFP 
and hDesmin-C2-GFP lentiviruses (Fig. 2A). We could therefore use GFP as surrogate for dystrophin expres-
sion. GFP was expressed at different intensities within SFFV-C1-GFP+ , hDesmin-C1-GFP+ , SFFV-C2-GFP+ 
and hDesmin-C2-GFP+ cell populations, suggesting that different virus copy numbers had integrated into each 
individual cell. An alternative explanation for the lower expression of dystrophin-GFP driven by the hDesmin 
promoter could be lower activity of the hDesmin promoter than the SFFV promoter in the context of the study. 
GFP was present within the cytoplasm in all groups of non-differentiated cells. Within CD133+ cells derived 
from a normal donor7, no dystrophin was present within non-differentiated cells (data not shown).
Dystrophin expression in transduced cells was verified by western blotting analysis using a GFP antibody 
(Fig. 2B) or dystrophin antibody (supplementary data Figure S3 and S4). The staining pattern of the two anti-
bodies was identical, therefore we used GFP as surrogate of dystrophin expression. Expression of C1 was barely 
detectable in hDesmin-C1-GFP transduced cells, whilst there were clear bands in SFFV-C1-GFP, SFFV-C2-GFP 
and hDesmin-C2-GFP transduced cells.
Dystrophin protein is expressed in cells undergoing myogenic differentiation in vitro. 
Full-length dystrophin was located in differentiated myotubes derived from normal CD133+ cells; no dystrophin 
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was present in non-differentiated cells within this culture (Fig. 3). However, within differentiated cultures derived 
from DMD pericytes that had been transduced with dystrophin C1 or C2 constructs, dystrophin-GFP was found 
within both myotubes and non-differentiated cells (Fig. 3).
Myotubes derived from normal CD133+ cells (thus expressing full length dystrophin driven by the endoge-
nous dystrophin promoter) had diffuse low fluorescent intensity within their cytoplasm, with stronger punctate 
signal along the membrane. However, dystrophins C1 and C2 were expressed throughout the cytoplasm of the 
myotube, with slightly stronger and punctate signal pattern at the membrane (Fig. 3).
SFFV-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP were expressed within the majority of 
fibres of donor origin in vivo. As the transduction efficiency of lentiviruses SFFV-C1-GFP, SFFV-C2-GFP 
and hDesmin-C2-GFP was high (more than 50% GFP+ cells), while the transduction efficiency of lentivirus 
hDesmin-C1-GFP was far lower (only 6.53% GFP+ cells) (Figure S1), we therefore FACS sorted GFP+ cells from 
the hDesmin-C1-GFP transduced population, and transplanted them in parallel with non-sorted SFFV-C1-GFP, 
SFFV-C2-GFP and hDesmin-C2-GFP cells into recipient mice.
One month after intra-muscular transplantation, donor-derived muscle fibres (expressing human spectrin) 
were present in all of the transplanted muscles. Co-staining of GFP and dystrophin showed that in muscles trans-
planted with SFFV-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP cells, the majority of the human spectrin+ 
fibres expressed dystrophin and GFP (Fig. 4A a–d); while in muscles transplanted with hDesmin-C1-GFP+ 
cells, there were similar numbers of fibres expressing human spectrin, but only a few of these expressed dystro-
phin (Fig. 4A e–h). The number of human spectrin+ fibres (mean ± SEM) was 178.3 ± 40.39, 118.8 ± 17.81, 
101.5 ± 40.05 and 92.50 ± 43.71 in SFFV-C1-GFP, hDesmin-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP cell 
Figure 1. Schematic illustration of mini-dystrophin constructs and the titration of lentivirus using 
different methods. (A) Schematic illustration of mini-dystrophin constructs compared to the full-length 
dystrophin. The sizes of mini-dystrophin constructs are given on the right. Individual deletions are outlined 
in grey and domains highlighted in different colors as indicated. (B) Titration of lentivirus using different 
methods, showing that the titration of the lentiviruses was limited by the size (bp) of the inserted transgene. 
NIGW: pRRL.SFFV.neo-IRES-GFP; SC2: SFFV-C2-GFP; DC2: hDesmin-C2-GFP; SC1: SFFV-C1-GFP; DC1: 
hDesmin-C1-GFP.
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transplanted groups, respectively (Fig. 4B), there were no differences among these groups (p = 0.3910, one way 
ANOVA). However, the number of GFP+ fibres (mean ± SEM) was 194.5 ± 35.24, 1.750 ± 0.4787, 164.8 ± 58.21 
and 125.3 ± 44.68 in SFFV-C1-GFP, hDesmin-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP cell transplanted 
groups (Fig. 4C); there were significant differences in the number of GFP+ fibres between SFFV-C1-GFP 
and hDesmin-C1-GFP (p = 0.0286, Mann-Whitney test), SFFV-C2-GFP and hDesmin-C1-GFP (p = 0.0294, 
Mann-Whitney test) as well as hDesmin-C2-GFP and hDesmin-C1-GFP (p = 0.0294, Mann-Whitney test) 
groups, suggesting that hDesmin-C1-GFP was not expressed in vivo. 
In transplanted muscles, all GFP+ fibres were dystrophin+ , but not all dystrophin+ fibres expressed GFP. 
This was because the dystrophin antibody that we used recognizes revertant muscle fibres that occur naturally 
in mdx muscles20,21,22. GFP is therefore a better marker for donor fibres than is dystrophin and we used GFP in 
subsequent experiments as a surrogate for donor-derived dystrophin.
Components of the dystrophin-associated glycoprotein complexes (DGC) are recruited in mus-
cle fibres expressing dystrophins C1 or C2. To determine whether the dystrophin expressed within 
regenerated muscle fibres in vivo was functional, we investigated whether the dystrophin-associated glycoprotein 
complex (DGC) was restored within these muscle fibres23. Both C1 and C2 contain the cysteine-rich domain, 
which are the binding sites for β -dystroglycan24,25, a major component of the DGC.
There was weak expression of the DGC components α -sarcoglycan, β -dystroglycan and γ -sarcoglycan on 
the sarcolemma of myofibres in non-transplanted mdx nude mouse muscles (data not shown), similar to mdx 
mice26–28. However, similar to regenerated muscles derived from normal CD133+ cells (data not shown), muscles 
that had been grafted with SFFV-C1-GFP (Fig. 5) SFFV-C2-GFP, and hDesmin-C2-GFP cells (data not shown) 
showed up-regulation of α -sarcoglycan, β -dystroglycan and γ -sarcoglycan in dystrophin+ fibres. There was a 
positive correlation between the expression intensity of these DGC proteins and the intensity of the GFP on the 
muscle fibres. There were almost no fibres expressing donor-derived dystrophin-GFP in muscles that were grafted 
with hDesmin-C1-GFP+ cells (Fig. 4), and no DGC restoration in these muscles.
Figure 2. Expression of dystrophin in lentivirally-transduced pericytes. (A) Confocal images of DMD 
pericytes that had been transduced with dystrophin lentivirus. GFP+ cells were FACS sorted and plated in 
culture, then fixed with 4% paraformaldehyde and stained with GFP (green) and dystrophin (red). Nuclei were 
counterstained with DAPI (blue). Scale bar = 20 μ m. SC1: SFFV-C1-GFP, DC1: hDesmin-C1-GFP, SC2: SFFV-
C2-GFP and DC2: hDesmin-C2-GFP. (B) Western blotting of GFP (upper lane) and Tubulin 2.1 (lower lane) 
on samples extracted from DMD pericytes which had been transduced with SFFV-C1-GFP (SC1); hDesmin-
C1-GFP (DC1); SFFV-C2-GFP (SC2) and hDesmin-C2-GFP (DC2) lentivirus. GFP+ cells were purified by 
FACS before sample preparation. Sample extracted from non-transduced (NT) pericytes was loaded as negative 
control. This is a cropped image; the full-length blot is presented in Supplementary Figure S2.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:19750 | DOI: 10.1038/srep19750
Figure 3. Expression of dystrophin in differentiating pericytes that had been transduced with SFFV-
C1-GFP (SC1); hDesmin-C1-GFP (DC1); SFFV-C2-GFP (SC2) and hDesmin-C2-GFP (DC2) lentivirus. 
Purified GFP+ cells from each cell preparation were induced to differentiate in culture for 7 days, and stained 
with antibodies to GFP (green), dystrophin (red) and myosin (MF20, cyan). hCD133+ cells derived from a 
normal donor were treated in parallel as positive control for the dystrophin staining. White arrows point to 
cells that express GFP and dystrophin, but did not express myosin and were not differentiated multinucleated 
myotubes. Nuclei were counterstained with DAPI (blue). Scale bar = 15 μ m.
Figure 4. Restoration of dystrophin in regenerated muscle fibres derived from lentivirally-transduced 
DMD pericytes. (A) shows representative transverse sections of cryodamaged muscles of an mdx nude mouse 
that had been grafted with a–d: SFFV-C1-GFP cells; e–h: hDesmin-C1-GFP cells. Muscles transplanted with 
SFFV-C2-GFP and hDesmin-C2-GFP cells showed similar staining pattern as that shown in a–d. Sections were 
stained with antibodies to human spectrin (red), GFP (green), dystrophin (cyan). Nuclei were counterstained 
with DAPI (blue). Scale bar = 15 μ m. (B) and (C) are the quantification of human Spectrin+ fibres (B) and 
GFP+ fibres (C) in SFFV-C1-GFP, hDesmin-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP cells transplanted 
groups. *p < 0.05.
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Recruitment of neuronal nitric oxide synthase (nNOS) on SFFV-C1-dystrophin expressing 
fibres. nNOS was absent at the sarcolemma of muscle fibres (apart from revertant fibres) of mdx nude mice, but 
was expressed on blood vessels (data not shown)29,30. To verify whether the presence of the nNOS binding motif 
(R16/17 of the spectrin repeats) on dystrophin C1 could effectively recruit nNOS to muscle fibres, we performed 
immunostaining of nNOS and GFP on muscle sections that had been grafted with transduced cells. The expres-
sion of nNOS was examined at one and two months after transplantation. To exclude the “host derived” nNOS 
on revertant, dystrophin+ fibres30, we only counted nNOS+ /GFP+ fibres within the grafted muscles. There 
were no nNOS+ /GFP+ fibres in muscles that had been transplanted with hDesmin-C1-GFP, SFFV-C2-GFP and 
hDesmin-C2-GFP cells (Fig. 6B). In all muscles that had been transplanted with SFFV-C1-GFP cells, nNOS+ /
GFP+ fibres were found. One month after cell transplantation, within 194.5 ± 35.24 GFP+ donor-derived fibres, 
there were 4.75 ± 1.80 nNOS+ /GFP+ fibres comprising 2.303 ± 0.51% of the total GFP+ fibres. Two months 
post-transplantation, within 131.0 ± 30.0 GFP+ donor-derived fibres, there were 16.75 ± 3.40 nNOS+ /GFP+ 
fibres (15.72 ± 5.29% of the total GFP+ fibres) (mean ± SEM, n = 4 muscles for each time point). There was 
no significant difference in the number of total GFP+ donor-derived fibres between one and two month after 
transplantation (Fig. 6A–e); however, there was a significantly higher percentage of dystrophin expressing fibres 
of donor origin expressing nNOS (nNOS+ /GFP+ fibres) at two than at one month after cell transplantation 
(p = 0.0256, Fig. 6A–f).
Discussion
In our cell transplantation mouse model, we have restored functional dystrophin in regenerated muscle fibres 
derived from DMD patient-derived stem cells that had been lentivirally-transduced with two novel dystrophin 
constructs. We further show that dystrophin transgene C1 which is larger than those that have been tested previ-
ously, can be put into a lentiviral vector, used to transduce human stem cells that, following their transplantation 
into dystrophin-deficient mouse muscle, give rise to functional dystrophin protein.
Although insertional mutagenesis does not seem to cause problems in some preclinical models for hematopoi-
etic stem cells31,32, it does remain a concern for clinical application of lentiviruses. However, there are other ways 
of reducing the risk of insertional mutagenesis33,34.
When generating the dystrophin lentiviruses, one problem we encountered was the effect of the insert size on 
the virus titre. It has been shown that lentiviruses are limited by the length of RNA that they can package, which 
is generally thought to drop at an increasing rate above a provirus length of 11 kb10,17. It is noteworthy that some 
of the dystrophin lentiviruses used in this investigation were in excess of this limit. The dystrophin constructs, 
when fused to EGFP and driven by the 1.8 kb hDesmin promoter, give a genomic RNA length of 12.851 kb for 
C1 (Δ R3R13) and 9.727 kb for C2 (Δ H2R23). These genomic RNA lengths are either in excess of, or just at the 
upper limit of lentiviral packaging capacity, with the length of the hDesmin-C1-GFP construct appearing to be 
Figure 5. Recruitment of members of the DGC in dystrophin-expressing fibres of donor origin. 
Representative transverse sections of muscles that had been transplanted with SFFV-C1-GFP donor cells, 
stained with antibodies to: GFP (green, a, f, k), α -sarcoglycan (α -SG, red, b), β -dystroglycan (β -DG, red, g) and 
γ -sarcoglycan (γ -SG, red, l). c, h and m are merged images of a and b; f and g; k and l, respectively. Nuclei were 
counterstained with DAPI (blue). Scale bar = 15 μ m. Muscles that had been transplanted with SFFV-C2-GFP, 
hDesmin-C2-GFP cells (not shown here) showed a similar staining pattern to SFFV-C1-GFP cell transplanted 
muscles. d, i and n: expression intensity of α -sarcoglycan (d), β -dystroglycan (i) and γ -sarcoglycan (n) was 
significantly higher in GFP+ compared to GFP- fibres in representative muscles that had been transplanted 
with SFFV-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP cells. The intensity of expression of each component 
of the DGC correlated positively to GFP intensity (e, j and o). ***p < 0.0001.
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incompatible with this gene transfer system. In order to enable efficient packaging of C1 and C2 into lentiviruses, 
these dystrophin constructs were also packaged into vectors driven by the SFFV promoter, which is approxi-
mately 1.4 kb smaller than the hDesmin promoter. The lentiviral genomic RNA of these constructs is 11.266 kb for 
SFFV-C1-GFP and 8.134 kb for SFFV-C2-GFP, which facilitated their application to this technology.
The effect of the insertion size on the lentivirus packaging efficiency was evident in both the transduction and 
transplantation experiments. As to the largest dystrophin construct, hDesmin-C1-GFP, we were unable to pro-
duce a virus of sufficient titre to transduce mdcs under the same conditions as the other treatments (supplemen-
tary Figure S1). Prior to transplantation into mdx mice, these cells were purified on the basis of GFP expression, 
to maximise the delivery of dystrophin-expressing cells. However, one month after transplantation, the majority 
of the donor muscle fibres were not expressing dystrophin or GFP (Fig. 4), which suggested that the expression of 
hDesmin-C1-GFP was not retained in the cells.
Figure 6. Recruitment of nNOS in dystrophin- expressing regenerated myofibres in vivo. (A) Recruitment 
of nNOS in SFFV-C1-GFP- expressing regenerated myofibres in vivo. (a–d): Fibres expressing nNOS 
(red, b, d) that were also GFP+ (green, a, c) on a representative transverse section of host muscle that had 
been cryodamaged and transplanted with SFFV-C1-GFP cells one month (a,b) or two months (c,d) previously. 
Nuclei were counterstained with DAPI (blue). Asterisks (*) indicate nNOS+ /GFP+ fibres. Scale bar = 15 μ m. 
(e) quantification of the number of GFP+ fibres in muscles that had been transplanted with SFFV-C1-GFP 
cells one or two months previously. There was no significant difference in the number of GFP+ fibres between 
the two time points, p = 0.2. (f) percentage of the GFP+ fibres that expressed nNOS. There was a significantly 
higher percentage of dystrophin- expressing fibres of donor origin that also expressed n-NOS, at two months 
than at one month after transplantation. *p = 0.0286. (B) nNOS was not expressed on regenerated muscle fibres 
of donor origin expressing either SFFV-C2-GFP (SC2) or hDesmin-C2-GFP (DC2). (a–c) double staining with 
antibodies to GFP (a) and nNOS (b) on a representative transverse section of muscle that had been transplanted 
with SC2 cells. (c) merged image of a and b. Nuclei were counterstained with DAPI (blue). Scale bar = 15 μ m. 
(d–f) double staining with antibodies to GFP (d) and nNOS (e) on a representative transverse section of muscle 
that had been transplanted with DC2 cells. (f) merged image of d and e. Nuclei were counterstained with DAPI 
(blue). Scale bar = 15 μ m.
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However, the delivery of dystrophin C1 was markedly improved when driven by the smaller sized 
SFFV promoter (supplementary Figure S1). The level of the transduction efficiency was equivalent to that of 
hDesmin-C2-GFP lentivirus and the integration of SFFV-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP lentivi-
rus appeared to be stable, given that nearly all of the donor fibres expressed dystrophin and GFP one month after 
transplantation (Fig. 4).
When the GFP+ cells were purified by FACS sorting and examined for their expression of dystrophin by 
immunostaining, all of the transduced groups contained cells expressing dystrophin. This is not unexpected, as 
transgene expression was under the control of either SFFV or hDesmin promoter; the SFFV promoter is ubiqui-
tous and the hDesmin promoter is expressed in myogenic cells that have not yet begun terminal differentiation16, 
as well as in differentiated myotubes and muscle fibres. This explains the strong expression of these dystrophins 
in the cytoplasm of both non-differentiated and differentiated cells. Nevertheless, these cells formed muscle after 
their transplantation in vivo, evidence that their muscle regenerative capacity was not noticeably compromised. 
In these regenerated muscle fibres, the dystrophin derived from the donor myonuclei was correctly localised at 
the sarcolemma of the muscle fibres. It should be noted that our cells contained a dystrophin-GFP fusion protein 
and although GFP itself may have a deleterious effect on the function of some types of cell35,36, it did not appear 
to affect the function of the skeletal muscle derived stem cells used in our study. A recent publication37 has indi-
cated that dystrophin is expressed in satellite cells and is important for regulating their asymmetric division, so 
expression of dystrophin within non-differentiated muscle stem cells derived from DMD patients might improve, 
rather than be deleterious to, their function.
Systemic delivery of autologous genetically-modified stem cells would be ideal for the treatment of DMD. 
However, using the same cells and mouse model that we use in this study, we found that cells delivered 
intra-arterially did not give rise to muscle in downstream muscles, but when delivered intra-muscularly, they 
contributed robustly to muscle regeneration6. This is in contrast to the findings of Dellavalle et al.5, using similar 
human cells and mdx host mice on a different immunodeficient background (discussed in Meng 20116). So, in 
this proof of principle study, we chose to use a delivery route (intramuscular delivery) that is effective for our cells 
and mouse model, in order to investigate the effects of the two novel dystrophin constructs.
In these experiments, the levels of donor cell engraftment are not high enough to effect physiological improve-
ment. Although some publications have reported increase in muscle strength in dystrophin-deficient mouse mus-
cles following very low-level engraftment of donor cells38, more recent work has indicated that there must be a 
minimum level of restored dystrophin to confer functional benefit to the muscle39,40. Using a mouse model with 
varying, low dystrophin levels due to skewed X-inactivation, it was shown that 20% of normal levels of dystrophin 
are needed to fully protect muscle fibers from exercise-induced damage41 . A recent paper shows that 15% of nor-
mal levels of dystrophin, homogenously located at the sarcolemma of muscle fibres throughout the muscle, are 
required in an mdx tibialis anterior muscle to protect against eccentric contraction-induced damage42. There was 
also a positive correlation between maximal specific force and dystrophin expression in muscles in which restored 
dystrophin was homogeneously expressed42. However, if not all fibres within a treated muscle are expressing dys-
trophin, the picture is rather different: indeed 65% of muscle fibres expressing an internally-deleted dystrophin 
protein provided protection against eccentric contraction-induced damage in the TA of mdx muscle43. Mouse 
satellite cells that had been transplanted intra-muscularly in a new, highly immunodeficient mdx mouse model 
gave rise to more than 1,000 dystrophin+ fibres in the transplanted muscles. These muscles had significantly 
greater maximal tetanic force and specific force than PBS-injected control muscles44. But in our experiments 
described here in which we had transplanted human pericytes into mdx nude host mice, dystrophin was only 
present in fewer than 200 fibres within transplanted muscles. We therefore decided not perform physiological 
measurements of our transplanted muscles, as the dystrophin was clearly below levels required to have a mean-
ingful clinical benefit. Instead, we investigated whether members of the DGC and nNOS were restored in muscle 
fibres expressing restored dystrophin, which is evidence that the dystrophin was functional45.
The transplantation efficiency of the SFFV-C1-GFP, SFFV-C2-GFP and hDesmin-C2-GFP cells was similar. 
Dystrophin restoration and recruitment of DGC within myofibres of donor origin was also comparable in grafts 
transplanted with cells expressing all three constructs (Figs 4 and 5). However, an important difference between 
regenerated myofibres expressing either C1 or C2 dystrophin was in the recruitment of nNOS. As expected, 
there was nNOS on donor fibres derived from SFFV-C1-GFP cells, but not on regenerated myofibres derived 
from either SFFV-C2-GFP or hDesmin-C2-GFP expressing cells (Fig. 6). This is not surprising, as the C1 con-
struct contains the rod domain of the nNOS binding site, which enables recruitment of nNOS on the dystrophin 
-expressing fibres13. Dystrophin C1 is therefore a novel dystrophin construct that can successfully recruit nNOS 
expression on muscle fibres in vivo. Furthermore, the number of nNOS+ /GFP+ fibres significantly increased 
with time post transplantation, in line with previous observations suggesting that the sarcolemmal localisation of 
nNOS may depend on the maturation of the muscle fibres46.
Our study provides proof of principle that a dystrophin gene introduced by a lentivirus into human skel-
etal muscle derived cells can mediate expression of functional dystrophin. The transplantation of autologous 
cells, engineered to express dystrophin, would be a potential therapeutic tool to treat a broad spectrum of DMD 
patients with different mutations. We report the application of two novel functional mini-dystrophin constructs 
in this system. In addition, our findings support the advantage of using the larger, more functional dystrophin 
C1, which contains the nNOS binding site, in combination with DMD muscle cells. The formation of functional 
dystrophin C1 protein, which recruits nNOS on muscle fibres in the mdx nude muscle environment, provides 
evidence that this novel construct C1 is a promising dystrophin construct with potential to be used in autologous 
stem cell transplantation to treat DMD.
It might be possible to combine AAV-mediated gene therapy with lentivirally-mediated stem cells for dystro-
phin restoration. AAV coding for microdystrophin can be delivered systemically47,48. AAV targets postmitotic 
muscle fibres, but not quiescent satellite cells49. Satellite cells are needed to maintain the myofibres; systemically 
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delivering AAV to the patients would leave the satellite cells untreated, which would lead to a net loss of dystro-
phin in muscle fibres with time. If AAV-dystrophin treated patients were also treated with autologous stem cells 
coding for dystrophin, the stem cells should be able to repair and maintain muscle fibres and lead to continued 
dystrophin expression throughout life. However, consideration would have to be given to the promoter and dys-
trophin constructs used for this strategy, particularly as lentivirus accommodates our C1 and C2 constructs, 
whereas AAV would not.
Materials and Methods
Ethics. Human cells were obtained from the MRC Centre for Neuromuscular Diseases Biobank. Tissue 
sampling was approved by the NHS National Research Ethics Service, Hammersmith and Queen Charlotte’s 
and Chelsea Research Ethics Committee: Setting up of a Rare Diseases biological samples bank (Biobank) for 
research to facilitate pharmacological, gene and cell therapy trials in neuromuscular disorders (REC reference 
number 06/Q0406/33) and the use of cells as a model system to study pathogenesis and therapeutic strategies for 
Neuromuscular Disorders (REC reference 13/LO/1826), in compliance with national guidelines regarding the use 
of biopsy tissue for research. All patients or their legal guardians gave written informed consent.
Mdx nude mice were bred and experimental procedures were carried out in the Biological Services Unit, 
University College London Institute of Child Health, in accordance with the Animals (Scientific Procedures) 
Act 1986. Experiments were approved by the UCL Animal Welfare and Ethical Review Body. Experiments were 
performed under Home Office licence number 70/7086.
Isolation and maintenance of human skeletal muscle derived pericytes. Human skeletal muscle 
derived cells (pD2) isolated from the extensor digitorum brevis muscle of an 11 year old DMD patient were used. 
These cells contribute to robust regeneration after intra-muscular transplantation into muscles of immunodefi-
cient host mice6. Cells were maintained in M10 medium (Megacell DMEM (Sigma, Dorset, UK) medium, 10% 
fetal bovine serum (Invitrogen, Paisley, UK), 2 μ M glutamine (Sigma, Dorset, UK), 1% non-essential amino acids 
(Sigma, Dorset, UK), 0.1 mM β - mercaptoethanol (Sigma, Dorset, UK) and 5 ng/ml basic fibroblast growth factor 
(PeproTech, London, UK). For transduction of dystrophin lentivirus, cells at a mean population doubling of 5.64 
or 13.13 were used.
Vector construct and preparation. The 7.4 kb C1/Δ R3-R13 and the 4.2 kb C2/Δ H2-R23 
mini-dystrophins (see detailed sequence in Supplementary data) were generated by splicing by overlapping 
extension (SOE-PCR) using human full-length dystrophin cDNA as template. The pRRL.sin.cppt.desmin.GFP 
construct15,16 was kindly provided by Michael Antoniou. The construction of pRRL.desmin.C2 was carried out by 
GeneArt cloning services (Life Technologies, Paisley, UK) (supplementary methods), and pRRL.desmin.C1 was 
constructed by cloning the respective regions from pCMV. 3Δ R3R13 into the pRRL.desmin.C2 construct. The 
GFP tag was fused to each vector using a standard cloning strategy. For promoter comparison, a SFFV-promoter 
was also cloned into the lentiviral vector backbone to generate SFFV-C1-GFP and SFFV-C2-GFP vectors.
Third-generation, VSV-G-pseudotyped lentiviral vectors were produced by co-transfecting the respective dys-
trophin plasmid into HEK 293T cells along with pMD2G, pRRE.MDL2 and pRSV.REV (a kind gift from Kathryn 
North)50,51. Plasmids were transfected in a 4:2:1:1 ratio, based on the molar mass of each plasmid. Vectors were 
purified by low-speed ultracentrifugation at 20,000xg over a sucrose cushion, as described previously10.
Viral titration. Vectors were titred by viral gRNA copy number, proviral copy number, integrated proviral 
copy number as well as functional titre (FACS) levels (supplementary methods).
FACS sorting and analysis. 7 days after transduction, cells were trypsinized and 5 × 104 cells were used 
for analysis of GFP expression using a LSRII FACS machine (BD Biosciences, Oxford, UK). Non-transduced 
cells were used to set the negative control gate. For in vitro analysis, GFP+ cells from cells transduced with each 
promoter/dystrophin construct (Figure S1) were sorted using a Moflo FACS sorting machine, and expanded 
in vitro for further analysis of dystrophin expression. All the FACS data were analyzed using Flowjo 7.2.5 software.
Immunofluorescence staining of dystrophin/GFP on cells and myotubes. After FACS sorting, 
GFP+ cells were expanded in vitro and were plated onto 50 μ g/ml poly-D-lysine coated 8-well chamber slides 
(Fisher Scientific, Loughborough, UK) in M10 medium at a density of 2 × 104 cells/well. Cells were fixed 24 hours 
after plating with 4% paraformaldehyde (PFA) (Sigma, Dorset, UK) for 15 min at room temperature.
To investigate the expression of dystrophin in differentiated myotubes, GFP+ cells from each preparation were 
plated onto 0.1 mg/ml Matrigel (BD Bioscience, Oxford, UK)-coated 8 well chamber slides in M10 medium at a 
density of 5 × 104 cells /well. Medium was changed into skeletal muscle cell differentiation medium (Promocell, 
Heidelberg, Germany) 24 hours after plating to induce myogenic differentiation. Cells were fixed with 4% PFA 7 
days later. Pericytes derived from normal human muscle would have been an ideal positive control, but for the 
fact that our preparations from normal muscle are not very myogenic (see Meng, 2011, Table 1)6. We therefore 
chose a preparation of normal human skeletal muscle-derived CD133+ cells7 that are as highly myogenic as the 
pericytes derived from the skeletal muscle of a DMD patient that we used in this study, as the positive control to 
show dystrophin in myotubes in vitro.
Fixed cells were blocked with 10% normal goat serum and 0.03% Triton X100 in PBS (blocking solution) for 
1 hour at room temperature. Chicken anti-GFP (1:1000, Abcam, Cambridge, UK), rabbit anti-dystrophin (1:1000, 
Fisher Scientific, Loughborough, UK) and mouse anti-myosin (MF20, 1:100, DSHB, Iowa City, Iowa) antibod-
ies diluted in blocking solution were then applied for 2 hours at room temperature. Alexa-488 conjugated goat 
anti-chicken IgG (H + L) antibody (1:500, Invitrogen, Paisley, UK), 594-conjugated goat anti-rabbit IgG (H + L) 
antibody (1:500, Invitrogen, Paisley, UK) and 647-conjugated goat anti-mouse IgG2b antibody (1:500, Invitrogen, 
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Paisley, UK) were then applied for 1 hour at room temperature before adding mounting medium (DAKO, Ely, 
UK) containing 10 μ g/ml 4′ ,6-diamidino-2-phenylindole (DAPI). Images were captured with a Zeiss confocal 
microscope.
Western blotting. To visualize the expression of dystrophin after transduction, GFP+ cells from each 
transduced population were plated onto 1 mg/ml Matrigel-coated 10 cm2 culture dishes (Fisher Scientific, 
Loughborough, UK) at a density of 1 × 106 cells /dish in M10 medium. Samples were collected 24 hours after 
culture. Protein was extracted in RIPA (Radio-Immunoprecipitation Assay) lysis buffer (Sigma, Dorset, UK) con-
taining a complete protease inhibitor cocktail (1:100, Roche, Welwyn Garden City, UK). 100 μ l of lysis buffer was 
added to each 10 cm2 culture dish, and left on ice for 10 minutes. Samples were collected and boiled for 3 minutes 
and then centrifuged at 14,000 g for 10 minutes at 4 °C. The supernatants were stored at − 20 °C until needed. 
30 μ l /well of each sample were loaded onto NuPAGE Novex 3–8% Tris-Acetate Gel, and run at a constant 
voltage of 150 V for 1 hour, before being transferred to a nitrocellulose membrane at 300 mA for 2 hours. The 
membrane was then blocked with Odyssey block solution (LI-COR Biosciences, Cambridge, UK) for 60min, 
incubated by a cocktail of primary antibodies of rabbit anti-GFP antibody (1:2000, Invitrogen, Paisley, UK) (or 
rabbit anti-dystrophin antibody, 1:2000, Fisher Scientific, Loughborough, UK) and mouse anti-tubulin (1:2000, 
Invitrogen, Paisley, UK) overnight at 4 °C. After washing with PBS containing 1% Tween 20 (PBST) for 15 min × 3 
times at room temperature, the membrane was then incubated with IRDye 680 RD goat anti-rabbit and IRDye 
800CW goat anti-mouse 2nd antibodies (1:15000, LI-COR Biosciences, Cambridge, UK) for 1–2 hrs at RT. The 
image of the blotted membrane was acquired by Odyssey Clx infrared imaging system (LI-COR Biosciences, 
Cambridge, UK) using image studio software 3.1.4.
In vivo transplantation and analysis. Intra-muscular transplantation of dystrophin transduced human 
pericytes. 4–8 week old mdx nude mice were used as recipients in this study. On the day of transplantation, 
mice were anaesthetized with isofluorane and tibialis anterior (TA) muscles of both hindlimbs were injured by 
cryoinjury as described previously52,53. 5 × 105 cells in 5 μ l culture medium were then injected into each TA with 
a Hamilton syringe. The skin was sutured after injection and the mice were kept warm until they had fully recov-
ered from the anaesthetic. For analgesia, Vetergesic (buprenorphine hydrochloride; 0.05 mg/kg body weight; 
Reckitt and Coleman, London, UK) was injected subcutaneously.
TA muscles were transplanted with pericytes that had been transduced with SFFV- C1-GFP, SFFV-C2-GFP, 
hDesmin C1-GFP and hDesmin-C2-GFP. In the hDesmin-C1 group, GFP+ cells purified by FACS sorting were 
used for grafting. Muscles were removed for analysis one month (n = 4 per group) after grafting. For examining 
the restoration of nNOS by donor fibres, muscles were analyzed at both one month (n = 4) and two months 
(n = 4) after grafting.
Analysis of muscle sections. Grafted TA muscles were dissected and frozen in isopentane pre-chilled in liquid 
nitrogen. 10 μ m transverse cryosections were cut throughout the muscle and stained with antibodies to human 
spectrin (Vector labs, VP-S283, 1:100, Peterborough, UK), GFP (1:1000, chicken polyclonal, Abcam, Cambridge, 
UK), poly-dystrophin (1:1000, Fisher Scientific, Loughborough, UK) followed by corresponding secondary 
antibodies (Alexa 488 conjugated goat anti-chicken IgG (H + L), Alexa 594 conjugated goat anti-mouse IgG 
(H + L), Alexa 647 conjugated goat anti-rabbit IgG (H + L), Invitrogen, Paisley, UK). To investigate the expres-
sion of DGC and nNOS, serial sections were stained with antibodies against α -Sarcoglycan (Leica Biosystems, 
clone Ad1/20A6, 1:100, Newcastle upon Tyne, UK)/GFP, γ -Sarcoglycan (Source Bioscience, 1:500, Nottingham, 
UK)/GFP, β -dystroglycan (Leica Biosystems, clone 43DAG1/8D5, 1:100, Newcastle upon Tyne, UK)/GFP and 
nNOS (Santa Cruz, NOS1 (R-20), 1:500, Middlesex, UK)/GFP, followed by corresponding secondary antibodies 
as described above. The intensity of the DGC proteins on GFP+ fibres and GFP- fibres were measured using 
MetaMorph software and compared within each muscle. Images were captured with MetaMorph software using 
a Leica microscope. The number of GFP+ fibres and nNOS+ fibres were counted in sections that contained the 
most positive fibres, using MetaMorph software. The data were analyzed by Mann-Whitney test using graphpad 
prism5 software.
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